Showing 71 - 80 of 83
A social tariff of EuroQol time trade-off (TTO) values was recently presented. We compared the social tariff and patient TTO values among 104 women with mild and severe menopausal symptoms. The social tariff and patient TTO values were elicited both after and before hormone replacement therapy...
Persistent link: https://www.econbiz.de/10005200085
This study addresses the question of willingness to pay (WTP) for hormone replacement therapy (HRT) in order to alleviate menopausal symptoms. The woman obtains utility from consumption of goods and health. The purchase of a treatment is represented as a shift in the health production function...
Persistent link: https://www.econbiz.de/10005200104
This paper discusses the definition, interpretation and computation of cost-effectiveness (CE) acceptability curves. A formal definition of the CE acceptability curve based on the net benefit approach is provided. The curve can be computed using parametric or non-parametric techniques and for...
Persistent link: https://www.econbiz.de/10005209238
This report presents a computer model for evaluating the cost-effectiveness (CE) of Hormone Replacement Therapy (HRT). The model is an extension of a previous model and includes also the risk of spine and wrist fracture. New Swedish data on risk of coronary heart disease and related mortality...
Persistent link: https://www.econbiz.de/10014159659
There are few studies investigating the consequences of osteoporotic (low bone density) fractures in terms of costs and health outcomes. The purpose of this Swedish pilot study is to assess the costs and quality of life related to fractures of the hip, spine, wrist and shoulder and further to...
Persistent link: https://www.econbiz.de/10005771160
Background: The Fracture Intervention Trial (FIT) showed that the bisphosphonate alendronate reduces the risk of fractures in women with low bone mass in the United States. <p> Objective: To estimate the cost-effectiveness (cost per life-year gained and cost per quality-adjusted life-year, QALY,...</p>
Persistent link: https://www.econbiz.de/10005771182
This paper shows that there exists a close relation between the net benefit and Fieller's methods for calculation of confidence intervals and performing hypothesis testing in cost-effectiveness analysis. The prices at which the net benefit confidence interval limits are equal to zero are...
Persistent link: https://www.econbiz.de/10005190911
This report presents a computer model for evaluating the cost-effectiveness (CE) of Hormone Replacement Therapy (HRT). The model is an extension of a previous model and includes also the risk of spine and wrist fracture. New Swedish data on risk of coronary heart disease and related mortality...
Persistent link: https://www.econbiz.de/10005423792
Objective: To investigate the cost effectiveness of adding the beta-blocker bisoprolol to standard treatment in patients with congestive heart failure (CHF). Design and setting: A cost-effectiveness study was based on the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), a randomised...
Persistent link: https://www.econbiz.de/10005590414
The cost-effectiveness of hormone replacement therapy (HRT) based on a societal perspective is reassessed based on new medical evidence found in the Women’s Health Initiative (WHI). Within a model framework using an individual state transition model the cost-effectiveness of 50-60 year old...
Persistent link: https://www.econbiz.de/10005649123